Clinical and Translational Epidemiology Branch (CTEB)

The Clinical and Translational Epidemiology Branch (CTEB) focuses on etiologic and genomic factors that influence cancer progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions.

CTEB's mission is to plan, develop, direct, coordinate, and evaluate:

  • A comprehensive program of epidemiologic research in human populations related to etiologic and genomic factors that influence cancer progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions;
  • A program of epidemiologic research to study differences in cancer susceptibility and risk in individuals and populations and the multiple environmental and genetic factors that jointly contribute to development of cancer among individuals with underlying diseases and conditions and progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions with the ultimate goal of elucidating cancer development and progression among people with these health conditions;
  • A program of extramural epidemiologic research to evaluate the association of and magnitude of cancer risk associated with biomarkers of cancer development and progression in individuals with underlying diseases and cancer; and
  • Resources, infrastructures, and consortia with a focus on cancer development and progression in individuals with underlying diseases and cancer to facilitate and maximize the scientific potential of cancer epidemiology research.

Its mission also is to disseminate findings from the research supported by the Branch to the public, health care professionals, scientists engaged in cancer control, and the public health community.

The populations studied in the grants in CTEB are primarily patient populations - individuals who have had cancer, have premalignant conditions or certain chronic or genetic diseases that may predispose to cancer, or have experienced certain treatments, such as immunosuppression after organ transplants, that may predispose to cancer.


CTEB Staff

Branch Name / Title / Contact Info Interest Areas
CTEB

Freedman, Andrew N., Ph.D.
Branch Chief

Phone: (240) 276-6697
Email: freedmaa@mail.nih.gov

  • Developing, applying, and evaluating prediction models for cancer risk and prognosis
  • Developing benefit/risk indices for pharmaceuticals used to prevent and treat cancer
  • Identifying clinical, epidemiologic, and pharmacogenomic factors related to cancer treatment outcomes
CTEB

Bradley, Marie, Ph.D., M.P.H., M.Pharm.
Cancer Prevention Fellow

Phone: (240) 240-6883
Email: bradleymc@mail.nih.gov

  • Effects of routinely used medications on cancer risk and disease prevention
  • Adverse and/or long-term effects of chemotherapeutic and other pharmacologic agents used in the treatment of cancer
CTEB

Cook, Allison
Extramural Support Specialist

Phone: (240) 276-6687
Email: cookal@mail.nih.gov

  • Cancer and the Environment
  • Global Health
  • Risk Communication about Environmental Public Health
  • Long-term Effects of Exposure to Radiation and Toxins
  • Food Security
  • Urban Public Health Systems
CTEB

Watters Elena, Joanne, Ph.D., M.P.H.
Program Director

Phone: (240) 276-6818
Email: wattersj@mail.nih.gov

  • Dietary and lifestyle risk factors related to cancer progression, recurrence, and survival outcomes
CTEB

Filipski, Kelly K., Ph.D., M.P.H.
Program Director

Phone: (240) 276-6841
Email: filipskikk@mail.nih.gov

  • Pharmacogenomic factors related to cancer treatment outcomes and toxicity
CTEB

Marcus, Pam, Ph.D.
Program Director

Phone: (240) 276-6901
Email: marcusp@mail.nih.gov

  • Cancer epidemiology and screening
  • Cancer risk in persons with chronic conditions
  • Operations and management of large, multicenter initiatives, including clinical trials
  • Lung cancer
CTEB

Rivera, Donna, PharmD.
Cancer Research Training Award Fellow

Phone: (240) 276-7674
Email: donna.rivera@nih.gov

  • Cancer Epidemiology
  • Pharmacoepidemiology
  • Pediatric Pharmacotherapy
  • Breast Cancer
  • Genetic Biomarkers
  • Chemotherapeutics
  • Risk Modeling
  • Adverse Events
  • Women's Health
  • Patient Safety
CTEB

Shelburne, Nonniekaye F., C.R.N.P., M.S., A.O.C.N.
Program Director

Phone: (240) 276-6897
Email: nshelburne@mail.nih.gov

  • Epidemiology and benefit-risk prediction models for clinical oncology practice related to cancer treatment outcomes and toxicity and translation into clinical oncology practice

Return to Top